Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for hard numbers on Microbot Medical’s cash runway or the latest patent additions behind its LIBERTY micro-robotic platform? Investors typically start with the 10-K annual report, but wading through hundreds of pages of R&D tables can be time–consuming. Our SEC filings hub anticipates that journey and answers the common search, “Microbot Medical SEC filings explained simply,” with clear context for every document.
The moment a Microbot Medical quarterly earnings report 10-Q filing or an 8-K material event posts to EDGAR, Stock Titan delivers real-time access plus AI-powered summaries that translate clinical trial jargon into plain language. Need to monitor executive moves? Track every Microbot Medical insider trading Form 4 transactions notice alongside Microbot Medical Form 4 insider transactions real-time alerts so you never miss a buy or sell.
- See R&D expense trends with “Microbot Medical earnings report filing analysis.”
- Review patent milestones and regulatory disclosures through “Microbot Medical 8-K material events explained.”
- Compare leadership pay packages inside the “Microbot Medical proxy statement executive compensation.”
Each filing page pairs the original PDF with an easy-to-scan AI digest—ideal for understanding Microbot Medical SEC documents with AI when minutes matter. Whether you’re deciphering a Microbot Medical annual report 10-K simplified section on intellectual property or spotting patterns in a Microbot Medical executive stock transactions Form 4, our platform connects the dots, surfaces key figures, and updates automatically. Stop searching multiple sources; everything you need is organized in one place, refreshed the instant Microbot Medical submits a new disclosure.
Microbot Medical Inc. filed a Form D reporting a completed Regulation D private offering under Rule 506(b). The issuer raised aggregate proceeds of $25,244,903, of which $25,244,903 has been sold and $0 remains. The filing states the total offering amount reflects the aggregate exercise price of inducement preferred investment options and placement-agent preferred investment options. The placement agent received cash fees totaling $2,095,542 and was also granted 1,342,694 preferred investment options exercisable for common stock at prices ranging from $1.875 to $2.6625. The offering was a new notice with a first sale date of 2025-09-16, claimed a minimum investment of $0, and was not part of a business combination. The Form D was signed by CFO Rachel Vaknin on 2025-09-29.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
